Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 393-400

  Hao, Qin ^a   Mckenzie, Raymond ^a   Gan, Huachen ^a   Tang, Hua ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Breast cancer; Protein kinase D; Triple negative breast cancer cells

Indexed keywords

ISOPROTEIN; PROTEIN KINASE D; PROTEIN KINASE D2; PROTEIN KINASE D3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; ISOENZYMES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84875878730     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rozengurt E, Rey O and Waldron RT: Protein kinase D signaling. J Biol Chem 280: 13205-13208, 2005.
2. Sturany S, Van Lint J, Muller F, Wilda M, Hameister H, Hocker M, Brey A, Gern U, Vandenheede J, Gress T, Adler G and Seufferlein T: Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem 276: 3310-3318, 2001.
3. Auer A, von Blume J, Sturany S, von Wichert G, Van Lint J, Vandenheede J, Adler G and Seufferlein T: Role of the regulatory domain of protein kinase D2 in phorbol ester binding, catalytic activity, and nucleocytoplasmic shuttling. Mol Biol Cell 16: 4375-4385, 2005.
4. Rey O, Yuan J, Young SH and Rozengurt E: Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists. J Biol Chem 278: 23773-23785, 2003.
5. von Blume J, Knippschild U, Dequiedt F, Giamas G, Beck A, Auer A, Van Lint J, Adler G and Seufferlein T: Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. EMBO J 26: 4619-4633, 2007.
6. Papazyan R, Rozengurt E and Rey O: The C-terminal tail of protein kinase D2 and protein kinase D3 regulates their intracellular distribution. Biochem Biophys Res Commun 342: 685-689, 2006.
7. Eiseler T, Doppler H, Yan IK, Kitatani K, Mizuno K and Storz P: Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat Cell Biol 11: 545-556, 2009.
8. Ha CH, Wang W, Jhun BS, Wong C, Hausser A, Pfizenmaier K, McKinsey TA, Olson EN and Jin ZG: Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem 283: 14590-14599, 2008.
9. Wang S, Li X, Parra M, Verdin E, Bassel-Duby R and Olson EN: Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci USA 105: 7738-7743, 2008.
10. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN and McKinsey TA: Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24: 8374-8385, 2004.
11. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109: 1721-1728, 2007.
12. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
13. Irvin WJ Jr. and Carey LA: What is triple-negative breast cancer? Eur J Cancer 44: 2799-2805, 2008.
14. Eiseler T, Doppler H, Yan IK, Goodison S and Storz P: Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res 11: R13, 2009.
15. Hao Q, Wang L, Zhao ZJ and Tang H: Identification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis. J Biol Chem 284: 799-806, 2009.
16. Tang H, Hao Q, Rutherford SA, Low B and Zhao ZJ: Inactivation of SRC family tyrosine kinases by reactive oxygen species in vivo. J Biol Chem 280: 23918-23925, 2005.
17. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319-326, 2007.
18. Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, Wipf P and Wang QJ: Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol 10: 5, 2010.
19. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ and Johannes FJ: Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase C isoenzymes. FEBS Lett 392: 77-80, 1996.
20. Ha CH, Jhun BS, Kao HY and Jin ZG: VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis. Arterioscler Thromb Vasc Biol 28: 1782-1788, 2008.
21. Hao Q, Wang L and Tang H: Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol 296: C821-827, 2009.
22. Park JE, Kim YI and Yi AK: Protein kinase D1: a new component in TLR9 signaling. J Immunol 181: 2044-2055, 2008.
23. Tanaka M, Sagawa S, Hoshi J, Shimoma F, Matsuda I, Sakoda K, Sasase T, Shindo M and Inaba T: Synthesis of anilinomonoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett 14: 5171-5174, 2004.
24. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S and Rossi JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23: 222-226, 2005.
25. Rozengurt E: Protein kinase D signaling: multiple biological functions in health and disease. Physiology 26: 23-33, 2011.
26. LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P and Wang QJ: Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta 1806: 183-192, 2010.
27. Chen J, Deng F, Singh SV and Wang QJ: Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res 68: 3844-3853, 2008.
28. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K and Larsson C: PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 9: 76, 2010.
29. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M and Zauli G: Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 11: 185-199, 2011.
30. Ali AS, Ali S, El-Rayes BF, Philip PA and Sarkar FH: Exploitation of protein kinase C: A useful target for cancer therapy. Cancer Treat Rev 35: 1-8, 2009.